A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir

[Guest guest]

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1872-034X.2008.00332.x

Hepatology Research

OnlineEarly Articles

To cite this article: Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui,

Noriyuki Obara, Osamu Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori

Matsuda, Takayuki Kogure, Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo

Ashino, Tooru Shimosegawa (2008)

A case of HIV co-infected with hepatitis B virus precore/core deletion mutant

treated by entecavir

doi:10.1111/j.1872-034X.2008.00332.x

Abstract

Case Report

A case of HIV co-infected with hepatitis B virus precore/core deletion mutant

treated by entecavir

Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui, Noriyuki Obara, Osamu

Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori Matsuda, Takayuki Kogure,

Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo Ashino and Tooru

ShimosegawaDepartment of Internal Medicine, Tohoku University Hospital, Sendai,

Japan

Dr Yoshiyuki Ueno, Division of Gastroenterology, Department of Internal

Medicine, Tohoku University Hospital, Aoba-ku, Sendai 980-8574, Japan. Email:

yueno@...

The sequence of hepatitis B virus reported in this article has been deposited in

the DDBJ/EMBL/GenBank databases under accession number AB353732.

Abstract

We report a case of a HIV and hepatitis B virus (HBV)-co-infected patient to

whom entecavir (ETV) was administered initially before the notification

regarding the potential mutagenesis effect on HIV against the nucleoside analog.

Since initial evaluations indicated the advanced stage of chronic hepatitis B

and preserved numbers of peripheral CD4+ lymphocytes without the manifestation

of immunodeficiency, priority was given to the management of HBV. We started HBV

therapy with ETV at a dose of 0.5 mg daily without using any HIV drugs. The

viral loads of both HBV and HIV-1 decreased gradually during the 5 months

following the initial administration of ETV. HBV was well controlled by the

gradual replacement of ETV with highly-active antiretroviral therapy against HIV

with a regimen including atazanavir, emtricitabine, and tenofovir. HBV was

genotyped as A2 with the quasispecies pool consisting of the −1G precore/core

deletion mutant strain.

_________________________________________________________________

E-mail for the greater good. Join the i’m Initiative from Microsoft.

http://im.live.com/Messenger/IM/Join/Default.aspx?source=EML_WL_ GreaterGood

[Guest guest]

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1872-034X.2008.00332.x

Hepatology Research

OnlineEarly Articles

To cite this article: Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui,

Noriyuki Obara, Osamu Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori

Matsuda, Takayuki Kogure, Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo

Ashino, Tooru Shimosegawa (2008)

A case of HIV co-infected with hepatitis B virus precore/core deletion mutant

treated by entecavir

doi:10.1111/j.1872-034X.2008.00332.x

Abstract

Case Report

A case of HIV co-infected with hepatitis B virus precore/core deletion mutant

treated by entecavir

Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui, Noriyuki Obara, Osamu

Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori Matsuda, Takayuki Kogure,

Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo Ashino and Tooru

ShimosegawaDepartment of Internal Medicine, Tohoku University Hospital, Sendai,

Japan

Dr Yoshiyuki Ueno, Division of Gastroenterology, Department of Internal

Medicine, Tohoku University Hospital, Aoba-ku, Sendai 980-8574, Japan. Email:

yueno@...

The sequence of hepatitis B virus reported in this article has been deposited in

the DDBJ/EMBL/GenBank databases under accession number AB353732.

Abstract

We report a case of a HIV and hepatitis B virus (HBV)-co-infected patient to

whom entecavir (ETV) was administered initially before the notification

regarding the potential mutagenesis effect on HIV against the nucleoside analog.

Since initial evaluations indicated the advanced stage of chronic hepatitis B

and preserved numbers of peripheral CD4+ lymphocytes without the manifestation

of immunodeficiency, priority was given to the management of HBV. We started HBV

therapy with ETV at a dose of 0.5 mg daily without using any HIV drugs. The

viral loads of both HBV and HIV-1 decreased gradually during the 5 months

following the initial administration of ETV. HBV was well controlled by the

gradual replacement of ETV with highly-active antiretroviral therapy against HIV

with a regimen including atazanavir, emtricitabine, and tenofovir. HBV was

genotyped as A2 with the quasispecies pool consisting of the −1G precore/core

deletion mutant strain.

_________________________________________________________________

E-mail for the greater good. Join the i’m Initiative from Microsoft.

http://im.live.com/Messenger/IM/Join/Default.aspx?source=EML_WL_ GreaterGood